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Abstract: The objective of the present study was to evaluate sphingolipid levels 
(sphingosine-So and sphinganine-Sa) and to compare the Sa/So ratio in liver, serum and 
urine of Wistar rats after prolonged administration (21 days) of fumonisin B1 (FB1). In 
parallel, the kinetics of sphingolipid elimination in urine was studied in animals receiving 
a single dose of FB1. Prolonged exposure to FB1 caused an increase in Sa levels in urine, 
serum and liver. The most marked effect on sphingolipid biosynthesis was observed in 
animals treated with the highest dose of FB1. Animals receiving a single dose of FB1 
presented variations in Sa and So levels and in the Sa/So ratio. 
    
Keywords: Fumonisin B1, sphingolipids, biomarkers, Wistar rats, prolonged effect, 
single dose. 
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1. Introduction  
 
Fumonisins are a group of toxic metabolites produced by fungi of the genus Fusarium, especially F. 
verticillioides (Syn., F. moniliforme) and F. proliferatum [1, 2]. These species have been found in 
several agricultural products worldwide, especially in maize [3]. Among the fumonisins identified so 
far, fumonisin B1 (FB1) is considered to be the most toxic and the most abundant, representing ca. 70% 
of the total concentration in naturally contaminated food and feeds, followed by fumonisins B2 (FB2) 
and B3  (FB3). Ingestion of FB1 causes a variety of toxicosis in animals, including 
leukoencephalomalacia in horses [4], porcine pulmonary edema [5], and hepatocarcinoma and liver 
disease in rats [6]. Body weight and average daily weight gain have been shown to decrease in chicks 
in parallel with increasing dietary FB1 [7]. Hepatic and renal toxicity can be observed in several 
species, including rats, broilers, turkeys and ducks [8]. Additionally, the occurrence of FB1 in foods 
has been statistically associated with a high incidence of human esophageal cancer [9-11]. On the basis 
of existing toxicological evidence, the International Agency for Research on Cancer (IARC) has declared 
that F. verticillioides toxins are potentially carcinogenic to humans (Group 2B carcinogens) [12]. 
Due to its analogous structure to the precursor bases of sphingolipids, FB1 is able to block ceramide 
synthase, an enzyme that catalyzes the acylation of sphingosines (So) within the biosynthetic pathway 
of sphingolipids, causing immediate effects such as the depletion of complex sphingolipids, an 
increase in free sphinganines (Sa), or reduced reacylation of So [13-18]. Inhibition of ceramide 
synthase, results in an increase of cellular Sa concentration and, occasionally, a less pronounced 
increase of So, with a consequent increase in the Sa to So ratio [19]. Since the accumulated Sa cannot 
be completely metabolized, part of it is released into the extracellular medium, a fact that permits the 
detection of this compound in urine, tissue and blood [20-22]. These changes are observed before the 
occurrence of other biochemical indicators of cytotoxicity and the Sa/So ratio is thus an indicator or 
functional biomarker of exposure to toxic levels of fumonisin, although it is inefficient since 
fumonisins are eliminated from the organism immediately after ingestion [19, 22, 23]. Carcinogenicity 
is related to the accumulation of sphingoid bases (So and Sa) that trigger unprogrammed DNA 
synthesis, alterations in signaling mechanisms (cyclic AMP) and inhibition of protein kinase C, events 
culminating in the interruption of the normal cell cycle [24].  
According to Shephard et al. [18] the elevation of Sa or of the Sa/So ratio is a useful biomarker in 
animal studies where exposures or doses are high. However, exposure in most human populations may 
be too low to produce marked changes in these parameters, which are naturally present in human 
physiological fluids. Solfrizzo et al. [20] concluded that, although the urine samples from areas with 
high maize consumption showed mean Sa/So ratio significantly higher as compared to low or no maize 
consumption areas, further studies is necessary before the Sa/Sa ratio can be considered a useful 
biomarker of fumonisin exposure in human. 
According Pozzi et al. [25] the kidneys were affected by the joint action of AFB1 and FB1 in Wistar 
male rats and to some authors male rats are more susceptible than female rats to the nephrotoxic action 
of FB1. They observed that renal lesions appear to be more marked lower doses of FB1 in males, 
whereas the study was performed in Fischer 344 rats and B6C3F mice and kidney toxicity was studied 
in Sprague-Dawley rats [26-28]. The kinetics of fumonisin B1 after a single oral dose of 10 mg FB1/kg 
in male Wistar rats were studied by Martinez-Larranaga et al. [29] that observed almost 15 time more Int. J. Mol. Sci. 2009, 10  
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FB1 in the kidney than the liver. In view of the importance of investigations about biomarkers to 
fumonisin B1 exposure, the objective of the present study was to evaluate the levels of sphingolipids in 
urine, serum and liver of Wistar rats submitted to prolonged and single oral dose of fumonisin B1.  
 
2. Materials and methods 
 
2.1. Mycotoxins 
 
Purified FB1 (>95%) administrated to rats was purchased from the Programme on Mycotoxins and 
Experimental Carcinogenesis (PROMEC, Tygerberg, South Africa).  
  
2.2. Animals and diet 
 
Fifty male Wistar rats with at 45 days of age a mean weight of 150 g, obtained from the Central 
Animal House of the State University of Campinas (UNICAMP), were studied. Thirty animals were 
used for the evaluation of the effects of prolonged exposure and 20 for the study of the effects of a 
single FB1 dose. The animals were divided into five groups and housed in cages of five animals each, 
with water and commercial chow being available ad libitum. In the case of animals submitted to 
prolonged exposure (21 days), urine, serum and liver tissue were collected before and 21 days after 
administration. In the case of animals used in the single dose assay, urine was collected at 24-hour 
intervals during the 96-hour administration period. The urine collection was performed by containment 
and by spontaneous urination. The diets especially prepared for rats by Nuvital Nutrients S/A were 
analyzed for the presence of aflatoxinas, ochratoxins, sterigmatocystin, zearalenone [30] and 
fumonisins [31]. The study was approved by the Institutional committee on the Care and Use of 
Laboratory Animals of the University of São Paulo.  
 
2.3. Experimental protocol 
 
All animals received FB1 solution in sterile saline by gavage, and were sacrificed under anesthesia 
with 3% sodium pentobarbital. The animals were divided into the following experimental groups: 
Prolonged exposure: the animals were divided into three groups – control group I (GI - no mycotoxins 
– control), group II (GII - 5 mg FB1/kg b.w. /day), and group III (GIII - 10 mg FB1/kg b.w. /day); 
Single dose: the animals were divided into two groups: group I (no mycotoxins – control) and group II 
(5 mg FB1 /kg b.w). 
 
2.4. Sphingolipid analysis  
 
The total amounts of sphingosine (So) and sphinganine (Sa) in liver, serum and urine were 
determined as described by Riley et al. [32] and Castegnaro et al. [33, 34]. The extracts were 
derivatized with reactive OPA and analyzed by HPLC analysis on a Supelcosil LC18 reverse-phase 
column according to Shephard and Van Der Westhuizen [35] using a mobile phase of methanol and 
water (9:1, v/v) at a flow rate of 1 mL/min. Sphinganine (DL-erythrodihydrosphingosine) and Int. J. Mol. Sci. 2009, 10  
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sphingosine (D-sphingosine), used as standards, were obtained from Matreya Inc. The amounts of 
sphinganine and sphingosine were calculated using the relative areas of the unknowns vs the C20 
sphinganine internal standard. 
 
2.5. Statistical analysis 
 
Analysis consisted of a 2 × 2 factorial scheme in a fully randomized design, with four replicates 
calculated on a case by case basis. Analysis of variance (Tukey test) was performed combining the 
treatments used with the liver, serum and urine samples by order.  
 
3. Results  
 
3.1. Prolonged effect 
 
The prolonged administration of FB1 (groups II and III) resulted in an increase of Sa levels in urine, 
serum and liver or rats treated with the toxin compared to the control group. In addition, mean Sa 
levels were higher than the observed So concentrations. The highest concentrations of Sa were 
detected in serum (38.03 ng/mL), liver (27.73 ng/mL) and urine (23.54 ng/mL) of group III animals 
administrated with the highest FB1 dose (10 mg/kg). With respect to So, the highest levels were 
observed in rats treated with the lower FB1 dose (5 mg/kg), especially in serum (24.53 ng/mL). The 
highest Sa/So ratios were observed in urine (8.03) of group III animals inoculated with the higher FB1 
concentration (Table 1). 
 
Table 1. Mean sphingosine (So) and sphinganine (Sa) levels and mean Sa/So ratio in urine, 
liver and serum or rats submitted to prolonged exposure (21 days) to FB1. 
Material Group  So (ng/mL)  Sa (ng/mL)  Sa/So 
 
Urine (n=10) 
I  13.01
a (± 4.27)  7.30
c (± 3.18)  0.56
c (± 0.19) 
II  7.08
c (± 1.25)  17.95
ab (± 0.57)  2.53
b (± 0.52) 
III  2.93
c (± 1.25)  23.54
a (± 8.28)  8.03
a (± 1.35) 
 
Serum (n=10) 
I  9.12
c (± 3.93)  3.09
c (± 3.12)  0.34
c (± 0.21) 
II  24.53
a (±11.49) 34.49
a (± 21.59)  1.40
b (± 0.24) 
III  21.67
a (± 21.25)  38.03
a (± 26.59)  1.75
a (± 4.83) 
 
Liver (n=10) 
I  9.20
b (± 3.82)  1.67
c (± 0.84)  0.18
c (± 0.12) 
II  4.81
c (± 2.91)  13.85
b (± 6.73)  2.90
b (± 1.56) 
III  4.79
c (± 1.82)  27.73
a (± 8.71)  5.80
a (± 2.43) 
Group I:
 control; group II: 5 mg FB1/kg b.w.; group III: 10 mg FB1 /kg b.w. 
Means followed by the same letters in the same column, in each clinical material, did not differ significantly 
by the Tukey test (p < 1%). 
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3.2. Single dose 
 
Mean urinary So concentrations were below the values observed in the first sampling (T0) in 
animals receiving a single dose of FB1 (5 mg/kg b.w.). In contrast, Sa levels showed a significant 
increase (p<0.05) 48 hours after the administration of the toxin (13.39 ng/mL), reaching a maximum 
level at 72 hours (30.46 ng/mL) (Table 2). The same was observed for the Sa/So ratio, which reached 
maximum values at 72 hours (3.03) and tended to return to normal at the end of the study period 
(0.68). Mean Sa/So ratio in rats receiving a single dose of FB1 ranged between 0.57 to 3.03. 
Sa and So concentrations remained constant (p>0.05) in the control group (G I) throughout the 
study period with Sa/So ratio ranging from 0.57 to 0.63 with value close to those observed in T0.  
 
Table 2. Mean sphingosine (So) and sphinganine (Sa) levels and urine Sa/So ratio in 
rats receiving a single dose of FB1. 
Time (hours)  So  Sa  Sa/So 
0 10.52
a ±4.70*
  6.05
c ±0.87
  0.57
c ±0.24 
24 3.55
c ±1.97  6.64
c ±2.87  1.9
ab ±0.89 
48 7.34
b ±0.70  13.39
b ±1.39  1.82
ab ±0.33 
72 10.03
a ±3.12  30.46
a ±9.88  3.03
a ±0.72 
96 8.64
b ±4.77  5.87
c ±0.73  0.68
c ±0.83 
n = 10 animals. 
Group II: 5 mg FB1/kg b.w./day. 
Sa and So are reported as ng/mL. 
Means followed by the same letters in the same column did not differ significantly by the Tukey 
test (p >0.01). 
 
4. Discussion 
 
Rats have been used over decades as an experimental model in mycotoxicology studies, especially 
investigations on aflatoxins [24], and were also employed in the first studies on fumonisins conducted 
by Gelderblom et al. [1] in South Africa. The choice of the use of male rats in the present study was 
based on previous investigations demonstrating a higher sensitivity of males to the effects of 
fumonisins compared to females [36]. Furthermore, Riley et al. [13] studying differences in FB1 
sensitivity between sexes in Sprague-Dawley rats, observed higher Sa levels and a higher Sa/So ratio 
in male rats compared to female animals. Differences in the responses to FB1 between sexes of the 
same animal strain have also been demonstrated by Tolleson et al. [37]. In order to characterize the 
effect of natural intoxication on the synthesis of sphingolipids, we chose to administer the toxin by the 
oral route over 21 days. The FB1 doses were selected based on the literature in which the most notable 
effects of FB1 were observed in liver, bone marrow, adrenal glands and kidneys, with doses ranging 
from 1 to 75 mg FB1/kg b.w./day administered for 14 days [38, 39]. 
The effects of FB1 have been investigated since its discovery in 1988 by Gelderblom et al. [1]. 
Although studies in this area are still incipient, the observation of the blockade of sphingolipid Int. J. Mol. Sci. 2009, 10  
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synthesis has clarified the origin of some lesions and physiological alterations resulting from FB1 
intoxication [40].  
FB1, by reacting with ceramide synthase (N-acyltransferase), the key enzyme of the sphingolipid 
biosynthetic pathway, triggers various signaling mechanisms for cell damage [41], causing the 
accumulation of immediate ceramide precursors, mainly Sa which is no longer acylated after its 
formation. The increase in the concentration of this precursor triggers a chain of events that are aimed 
at eliminating this substance which has become harmful to the cells, with the production of sphingosin-
1-phosphate as the main product functioning as a secondary intracellular messenger that regulates the 
mobilization of calcium and cell survival. Thus, the dynamic equilibrium between the sphingolipid 
metabolites ceramide and sphingosine-1-phosphate, which regulate opposite signaling mechanisms, is 
an important factor in the determination of cell survival or cell death [21]. Under normal conditions, 
these degradation reactions are efficient. However, in some situations FB1 blocks ceramide synthase 
and metabolization of the accumulated Sa, which is continuously produced. As a compensatory 
mechanism, Sa is released into the extracellular medium, which permits its detection in urine and 
blood. Increased concentrations of free sphingoid bases in serum, urine, liver and kidneys have been 
reported to be correlated with the severity of hepatotoxicity, nephrotoxicity or other indicators of 
cytotoxicity [40, 42]. 
This fact was also demonstrated in the present experiment in which an increase of Sa levels was 
observed in urine, serum and liver, especially in animals receiving the highest dose of the toxin (10 mg 
FB1/kg b.w./day, group III). Although urinary Sa levels (23.54 ng/mL) were below those detected in 
serum (38.03 ng/mL) and liver (27.73 ng/mL) in group III and the urinary Sa/So ratio was more 
pronounced (8.03). According to these data is possible to observe that the kidney is a potential target 
organ indicating a possible nephrotoxic effect of FB1. The accumulation of Sa and the increased 
urinary Sa/So ratio closely reflected the changes that occurred in the kidney, the organ most sensitive 
to fumonisin-induced sphingolipid alterations, as defined by Riley et al. [13]. In male Sprague-Dawley 
rat and Fischer 344N rats, the accumulation of sphingoid bases and toxicity in kidney are much greater 
than in liver, at the same dose [28]. 
Garren et al. [39] found no detectable alterations in the kidney Sa/So ratio in rats receiving doses of 
up to 0.5 mg FB1/kg b.w., whereas doses ranging from 1.0 to 5.0 mg/kg had an effect on the kidney but 
no apparent dose-response was observed (p < 0.0001), with the increase in the Sa/So ratio in the 
kidneys not reflecting changes in the urinary Sa/So ratio (3.3 to 4.5). 
Approximate urinary Sa/So ratios were observed in the present study when a dose of 5 mg FB1/kg 
was administered (2.53), whereas the dose of 10 mg/kg caused a 3-fold increase in the Sa/So ratio 
(8.03) (Table 1). Wang et al. [42] reported a significant increase of the Sa/So ratio in both kidney and 
urine of rats fed approximately 0.25 to 0.5 mg FB1/kg per day, while a diet containing 5 times lower 
FB1 levels resulted in a 2-fold increase of the Sa/So ratio in the kidney but no increase in urine. With 
respect to reversibility, the same author showed that in rats fed a dose of 10 µg FB1/g the levels of 
sphingoid bases returned to normal within a period of 10 days. Similar results have been reported by 
Garren et al. [39] who analyzed alterations in the Sa/So ratio in rat kidneys after the end of treatment 
with FB1. 
An elevated Sa/So ratio has also been detected in the liver, the organ apparently most affected by 
FB1 [43]. In the present study, prolonged administration of FB1 demonstrated a direct relationship Int. J. Mol. Sci. 2009, 10  
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between the doses of 5 and 10 mg/kg (groups II and III) and an increase in liver Sa/So ratio, with the 
higher dose causing a 2-fold increase (2.90 and 5.80, respectively), thus demonstrating the dose-
response sensitivity of this organ. The effect of FB1 on the biosynthesis of sphingolipids, as 
demonstrated by an increase of Sa levels and of the Sa/So ratio in urine, serum and liver, has also been 
observed by other investigators studying other species such as mammals and birds [44]. Different 
routes and frequencies of administration of FB1 influence the dose response in different species. 
Studies on rabbits have shown that the serum and urinary Sa/So ratio increased markedly compared to 
the control groups after intravenous administration of 1 mg FB1/kg w.b., for 5 days [45] and by gavage 
for 21 days [46]. On the other hand, the same dose administered by gavage to rats five times per week 
for 5 weeks resulted in no significant increase in the serum Sa/So ratio. Furthermore, only a marginal 
increase in serum Sa/So ratio was observed in rats receiving 16.8 mg FB1/kg b.w. three times per week 
by gavage [32].  
Our results demonstrated a 3 and 4.5 times lower serum Sa/So ratio, compared to the ratios found in 
urine and liver, respectively, even when the maximum dose (10 mg FB1/kg) was administered for 21 
days. Progressive increases in Sa and in the Sa/So ratio can be considered to be safe biomarkers for the 
evaluation of the effects of FB1 [48], even in the case of exposure to small doses. In rats, determination 
of the Sa/So ratio in urine and liver was found to be more sensitive than its determination in serum, 
probably due to the transitory state of the sphingoid bases in this material as a result of metabolization 
and excretion in rats. In contrast, Van der Westhuizen [47] demonstrated in monkeys that the plasma 
Sa/So ratio is a more sensitive biomarker of exposure to fumonisins than the urinary ratio. Urine levels 
of Sa/So ratio were more useful than serum levels in this present study. In despite of high levels of So 
and Sa in serum, the Sa/So levels were below in group II and III comparing to values of urine. In our 
experiment, the standard deviation of Sa/So level in serum very large can be attributed the low 
efficiency of extraction, fact indicated by Riley et al. [32], and also due to the majority of absorbed 
FB1 might bind to serum lipids or proteins, making undetectable as the free form [48]. The detected 
values of So, Sa, Sa/So in liver and urine were similar but urinary Sa/So ratio increased markedly 
compared to Sa/So in liver, as was observed in the animals that received 10 mg/kg b.w. Because of 
these difficulties, urine showed to be the best material for detection Sa/So ratio in Wistar rats. 
Administration of a single dose of FB1 (5 mg/kg b.w.) provoked changes in urinary Sa, So and 
Sa/So ratio within the first 24 hours. Maximum Sa levels (30.46 ng/mL) were observed after 72 hours, 
followed by a marked decline (5.87 ng/mL) at the end of the study period (96 hours), with the levels 
being below those detected at T0 (6.05 ng/mL). The Sa/So ratio showed a 3-fold increase in the first 24 
hours compared to baseline (from 0.57 to 1.90). After the ratio reached a maximum level at 72 hours 
(3.03), a marked reduction was observed until the end of the study period (96 hours), with the ratio 
tending to return to normal (0.68). In rats, many studies have showed the reversibility of damage in 
liver and kidney tissue induced by fumonisin [50]. The average of So values in single dose (24, 48, 72 
and 96 hours) was 7.39 ng/mL and in comparison with prolonged dose after 21 days (7.08 ng/mL) the 
data showed a similar tendency in the decrease of So in urine. There are few reports that discuss the 
kinetic of Sa/So ratio in rats exposed to a single dose of FB1, rendering difficult the comparative 
analysis with our study. Cai et al. [49] studying time course changes in urinary Sa/So, in F344 rats 
treated with single-dose FB1 (10 and 25 mg/kg), observed that urinary Sa/So began to increase at 12 h 
after administration, continually increased, reached a maximum on days 5 and 7, respectively, and Int. J. Mol. Sci. 2009, 10  
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decreased thereafter. The urinary Sa/So of rats in the high-dose group was significantly higher than of 
the low-dose group at days, 5,7 and 10, showing dose-dependent increases of Sa/So and this fact was 
also observed in some studies [32,39], according to our results that showed similar tendency of Sa/So, 
using low doses of FB1 (5 mg/kg).  
In the present study, urinary Sa/So also began to increase at 12 h after administration, continually 
increased, reached a maximum at 72 h. The interval between the maximum peak and decline in the 
Sa/So ratio was 24 hours and the return to normal within 96 h. Van der Westhuizen et al. [47], studied 
the effects of a single dose of FB1 (1 and 10 mg/kg) on Sa and So levels in vervet monkeys. The 
authors also observed a maximum peak in urinary Sa/So ratios at 72 hours, followed by a gradual 
decrease up to 120 hours, but the initial decline occurred in 96 hours. Cai et al. [49] and Delongchamp 
and Yong [51] reported that it is uncertain if the results obtained in rats can be extrapolated to larger 
animals since FB1 reported that the FB1 are rapidly eliminated from rats and mice while elimination in 
humans is believed to be slower.  
Garren et al. [39] observed a rapid decrease of the Sa/So ratio in rat kidney after cessation of daily 
exposure to 1 mg FB1/kg b.w. within 24 h after the end of treatment, but the Sa/So ratio only returned 
to normal after a period of 1 to 3 weeks. 
 
5. Conclusions 
 
Comparison of prolonged (group II) and single-dose treatment with FB1 revealed a similar mean 
urinary Sa/So ratio (2.53 and 3.03, respectively). This finding indicates an almost constant excretion 
rate of sphingoid bases, irrespective of the duration of treatment when the same dose was administered 
(5 mg FB1/kg in both cases). In addition, no marked differences in urinary So levels were observed 
between group II (prolonged treatment) and animals receiving a single dose, with So levels showing a 
slight decline over time (Table 1 and 2). This finding confirms that Sa is responsible for the increase in 
the Sa/So ratio as reported in the literature; however, in the present study this effect was observed both 
after prolonged exposure and after administration of a single dose of FB1. Urine was found to be a 
good material for the determination of the Sa/So ratio in male Wistar rats compared to liver and serum 
since higher urinary levels are observed with increasing doses (group III, 10 mg FB1/kg). Van der 
Westhuizen et al. [47] working with vervet monkeys, dosed with 10 mg FB1/kg body weight, in a 
single dose, observed that the urinary Sa/So ratios showing an earlier increase than the serum, peaked 
after two days (72 h) and rapidly declined thereafter to pre-dosing levels after four days. However, the 
urinary ratio returned to its original level within the seven-day experimental period. Cai et al. [49] 
showed that in rats F344, dosed with the same dose, a maximum of Sa/So in urine at five day (120 
hours), but the authors discussed that there are limited published data on Sa/So kinetics in 
experimental animals treated with single-dose FB1 to compare with their results. Our findings are 
significant, as observed in Wistar rats, which results approached to the monkeys data, receiving 5 mg 
FB1/kg b.w. besides, the kinetics of Sa/So showed that adverse effects are reversible after 72 h, as was 
observed in a single dose. The present work showed that male Wistar rats strains are good model to 
study about biosynthetic pathway of sphingolipids, and we suggest these animals to future researches 
about synergic effects of FB1 alone and in combination with other mycotoxins  to evaluate the 
detectable threshold limit of Sa/So and the time of reversibility in urine. Int. J. Mol. Sci. 2009, 10  
   
 
58
References and Notes   
1.  Gelderblom, W.C.A.; Jaskiewicz, K.; Marasas, W.F.O.; Thiel, P.G.; Horak R.M.; Vleggaar, R.; 
Kriek, N.P.J. Fumonisins — Novel mycotoxins with cancer promotion activity produced by 
Fusarium moniliforme. Appl. Environ. Microbiol. 1988, 54, 1806-1811. 
2.  Nelson, P.E.; Plattner, R.D.; Shackelford, D.D.; Desjardins, A.E. Fumonisin B1 production by 
Fusarium species other than F. moniliforme in Section Liseola a by some related species. Appl. 
Environ. Microbiol. 1992, 58, 984-989.  
3.  Marasas, W.F.O.; Kellerman, T.S.; Gelderblom, W.C.A.; Coetzer, J.A.W.; Thiel, P.G.; Van Der 
Lugt, J.J. Leukoencephalomalacia in horse induced by fumonisin B1 isolated from Fusarium 
moniliforme. Onderstepoort J. Vet. Res. 1988, 55, 197-203. 
4.  Kellerman, T.S.; Marasas, W.F.O.; Theil, P.G.; Gelderblom, W.C.A.; Cawood, M.; Coetzer; 
J.A.W. Leukoencephalomalacia in two horses induced by oral dosing of fumonisin B1. 
Onderstepoort J. Vet. Res. 1990, 57, 269-275. 
5.  Dilkin, P.; Zorzete, P.; Mallmann, C.A.; Gomes, J.D.F.; Utiyama, C.E.; Oetting, L.L.; Corrêa, B. 
Toxicological effects of chronic low doses of aflatoxin B1 and fumonisin B1 containing Fusarium 
moniliforme culture material in weaned piglets. Food Chem. Toxicol. 2003, 41, 1345-1353. 
6.  Gelderblom, W.C.A.; Lebepe-Mazur, S.; Snijman, P.W.; Abel, S.; Swanevelder, S.; Kriek, N.P.J.; 
Marasas, W.F.O. Toxicological effects in rats chronically fed low dietary levels of fumonisin B1. 
Toxicology 2001, 161, 39-51. 
7.  Ledoux, D.R.; Brown, T.P.; Weibking, T.S.; Rottinghaus, G.E. Fumonisin toxicity in broiler 
chicks. J. Vet. Diagn. Invest. 1992, 4, 330-333. 
8.  Tran, S.T.; Tardieu, D.; Auvergne, A.; Bailly, J.D.; Babilé, R.; Durand, S.; Benard, G.; Guerre, P. 
Serum sphinganine and the sphinganine to sphingosine ratio as a biomarker of dietary fumonisins 
during chronic exposure in ducks. Chem. Biol. Interact. 2006, 160, 41-50.  
9.  Rheeder, J.P.; Marasas, W.F.O.; Theil, P.G.; Sydenham, E.W.; Shephard, G.S.; Van Schalkwyk, 
D.J. Fusarium moniliforme and fumonisins in corn in relation to human esophageal cancer in 
Transkei. Phytopathology 1992, 82, 353-357. 
10.  Sydenham, E.W.; Theil, P.G.; Marasas, W.F.O.; Shephard, G.S.; Vanschalkwyk, D.J.; Koch, K.R., 
Natural occurrence of some Fusarium mycotoxins in corn from low and high esophageal cancer 
prevalence areas of the Transkei, Southern Africa. J. Agric. Food Chem. 1990, 38, 1900-1903. 
11. Marasas,  W.F.O.  Fumonisins: History, World-wide Occurrence and Impact. Jackson, L.S., de 
Vries, J.W., Bullerman, L.B., Eds.; Plenum Press: New York, 1996; volume 392, Chapter 1, pp. 
1-17. 
12. International Agency for Research on Cancer (IARC). Toxins Derived from Fusarium 
Moniliforme: Fumonisins B1 and B2 and Fusarin C (Group 2B), Monographs on the Evaluation of 
Carcinogenic Risks to Humans. IARC: Lyon, 1993; vol. 56, pp. 445. 
13.  Riley, R.T.; Hinton, D.M.; Chamberlain, W.J.; Bacon, C.W.; Wang, E.; Merrill, A.H., Jr.; Voss, 
K. Dietary fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: 
A new mechanism of nephrotoxicity. J. Nutr. 1994, 124, 594-603. Int. J. Mol. Sci. 2009, 10  
   
 
59
14.  Riley, R.T.; Wang, E.; Schroeder, J.J.; Smith, E.R.; Plattner, R.D.; Abbas, H.; Yoo, H.S.; Merrill 
A.H. Jr. Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity 
and carcinogenicity of fumonisins. Nat. Toxins, 1996, 4, 3-15. 
15.  Riley, R.T.; Voss, K.A.; Norred, W.P.; Sharma, R.P.; Wang, E.; Merrill, A.H., Jr. Fumonisins: 
Mechanism of mycotoxicity. Revue Méd. Vét. 1998, 149, 617-626. 
16. Merrill, A.H., Jr.; Wang, E.; Vales, T.R.; Smith, E.R.; Schroeder, J.J.; Menaldino. D.S.; 
Alexander, C.; Crane, H.M.; Xia, J.; Liotta, D.C.; Meredith, F.I.; Riley, R.T. Fumonisin Toxicity 
and Sphingolipid Biosynthesis.  Jackson, L.S., de Vires, J.W., Bullerman, L.B., Eds.; Plenum 
Press: New York, 1996; vol. 392, Chapter 4, pp. 297-306. 
17.  Turner, P.C.; Nikiema, P.; Wild, C.P. Fumonisin contamination of food progress in development 
of biomarkers to better assess human health risks. Mutat. Res. 1999, 443, 81-93. 
18.  Shephard, G.S.; Van Der Westhuizen, L.; Sewram, V. Biomarkers of exposure to fumonisin 
mycotoxins: A review. Food Addit. Contam. 2007, 24, 1196-1201. 
19.  Ribar, S.; Mesaric, M.; Bauman, M. High-performance liquid chromatographic determination of 
sphinganine and sphingosine in serum and urine of subjects from an endemic nephropathy area in 
Croatia. J. Chromatogr. B. 2001, 754, 511-519.  
20.  Solfrizzo, M.; Visconti, A.; Avantaggiato, G.; Torres, A.; Chulze, S. In vitro and in vivo studies to 
assess the effectiveness of cholestiramine as a binding agent for fumonisins. Mycopathologia 
2000, 151, 147-153. 
21.  Spiegel, S.; Milstien, S. Sphingosine-1-phosphate: signaling inside and out. FEBBS Letters, 2000, 
476, 55-57. 
22.  Shephard, G.S.; Theil, P.G.; Sydenham, E.W.; Savard, M.E. Fate of a single dose of 
14C-labeled 
fumonisin B1 in vervet monkeys. Nat. Toxins, 1995, 3, 145-150. 
23.  Wang, E.; Ross, F.; Wilson, T.M.; Riley, R.T.; Merrill, A.H., Jr. Increase in serum sphingosine 
and sphinganine and decrease in complex sphingolipids in ponies given feed containing 
fumonisins, mycotoxins produced by Fusarium moniliforme. J. Nutr. 1992, 122, 1706-1716.  
24. Hussein, H.S.; Brasel, J.M. Toxicity, metabolism and impact of mycotoxin on humans and 
animals. Toxicology 2001, 167, 101-134. 
25. Pozzi, C.R.; Corrêa, B.; Xavier, J.G.; Direito, G.M.; Orsi, R.B.; Matarazzo, S.V. Effects of 
prolonged oral administration of fumonisin B1 and aflatoxin B1 in rats. Mycopathologia 2000, 
151, 21-27. 
26. Voss, K.A.; Chamberlain, W.J.; Bacon, C.N.; Alberts, R.A.; Walters, D.B.; Norred, W.P. 
Subchronic feeding study of the mycotoxin fumonisin B1 in B6C3F mice and Fischer 344 rats. 
Fund. Appl. Toxicol. 1995, 24, 102-110. 
27.  Voss, K.A.; Howard, P.C.; Riley, R.T.; Sharma, R.P.; Bucci, T.J.; Lorentzen, R.J. Carcinogenicity 
and mechanism of action of fumonisin B1: a mycotoxin produced by Fusarium moniliforme (= F. 
verticillioides). Cancer Det. Prev. 2002, 26, 1-9. 
28.  Riley, R.T.; Voss, K.A. Differential sensitivity of rat kidney and liver to fumonisin toxicity: 
Organ-specific differences in toxin accumulation and sphingoid base metabolism. Toxicol. Sci. 
2006, 92, 335-345.  Int. J. Mol. Sci. 2009, 10  
   
 
60
29.  Martinez-Larranaga, M.R.; Anadon, A.; Diaz, M.J. Fernandez-Cruz, M.L.; Martinez, M.A.; Frejo, 
M.T.; Martinez, M.; Fernandez, R.; Anton, R.M.; Morales, M.E. Toxicokinetics and oral 
bioavailability of fumonisin B1.Vet. Hum, Toxicol. 1999, 41, 357-362. 
30. Soares, L.M.V.; Rodrigues-Amaya, D. Survey of aflatoxins, ochratoxin A, zearalenone and 
sterigmatocystin in some Brazilian foods by using multitoxin thin layer chromatographic method. 
J. Assoc. Off. Anal. Chem. 1989, 72, 22-26.  
31. Sydenham, E.W.; Shephard, G.S.; Thiel, P.G. Liquid Chromatographic determination of 
fumonisins B1, B2 and B3 in corn. J. Assoc. Off. Anal. Chem. 1996, 79, 688-696. 
32.  Riley, R.T.; Wang, E.; Merrill, A.H., Jr. Liquid chromatographic determination of sphinganine 
and sphingosine: Use of the free sphinganine-to-sphingosine ratio as a biomarker for consumption 
of fumonisins. AOAC Int. 1994, 77, 533-540. 
33.  Castegnaro, M.; Garren, L.; Galendo, D.; Gelderblom, W.C.A.; Chelule, P.; Dutton, M.F.; Wild, 
C.P. Analytical method for the determination of sphinganine and sphingosine in serum as a 
potential biomarker for fumonisin exposure. J. Chromatogr. B 1998, 720, 15-24.  
34. Castegnaro, M.; Garren, L.; Gaucher, I.; Wild, C.P. Development of a new method for the 
analysis of sphinganine and sphingosine in urine and tissues. Nat. Toxins 1996, 4, 284-290. 
35. Shephard, G.S.; van der Westhuizen, L. Liquid chromatographic determination of the 
sphinganine/sphingosine ratio in serum. J. Chromatogr. B., 1998, 710, 219-222. 
36.  Voss, K.A.; Plattner, R.D.; Riley, R.T.; Meredith, F.I.; Norred, W.P. In vivo effects of fumonisin 
B1- producing and fumonisin B1- nonproducing Fusarium moniliforme isolates are similar: 
Fumonisins B2 and B3 cause hepato and nephrotoxicity in rats. Mycopathologia, 1998, 141, 45-58. 
37.  Tolleson, W.H.; Dookey, K.L.; Sheldon, W.G.; Thurman, J.D.; Bucci, T.J.; Howard, P.C. The 
Mycotoxin Fumonisin Induces Apoptosis in Cultures Human Cells and Livers and Kidneys of 
Rats. Jackson, L.S., De Vries, J.W., Bullerman, L.B., Eds.; Plenum Press: New York,  1996; 
Volume 392, Chapter 4, p.237. 
38. Bondy, G.S.; Suzuki, C.A.M.; Fernie, S.M.; Armstrong, C.L.; Hierlihy, S.L.; Savard, M.E.; 
Barker, M.G. Toxicity of fumonisin B1 to B6C3F1 mice: A 14 day gavage study. Food Chem. 
Toxicol. 1997, 35, 981-989. 
39.  Garren, L.; Galendo, D.; Wild, C.P.; Mastegnaro, M. The induction and persistence of altered 
sphingolipid biosynthesis in rats treated with fumonisinB1. Food Addit. Contam. 2001, 18, 850-856. 
40.  Riley, R.T.; Enongene, E.; Voss, K.A.; Norred, W.P.; Meredith, F.I.; Sharma, R.P.; Spitsbergen, 
J.; Williams, D.E.; Carlson, D.B.; Merrill, A.H., Jr. Sphingolipid perturbation as mechanism for 
fumonisin carcinogenesis. Environ. Health Perspect. 2001, 109, 301-308. 
41.  Merrill, A.H., Jr.; Schmelz, E.M.; Dillehay, D.L.; Spiegel, S.; Shayman, J. A.; Schroeder, J. J.; 
Rilley, R. T.; Voss, K. A.; Wang, E. Sphingolipids — The enigmatic lipid class; Biochemistry, 
Physiology and Pathophysiology. Toxicol. Appl. Pharmacol. 1997, 142, 208-225.  
42.  Wang, E.; Riley, R.T.; Meredith, F.I.; Merrill, A.H., Jr. Time course dependence, and reversibility 
of increases in urinary sphinganine and sphingosine in animals fed defined diets containing 
fumonisin B1: Characteristics of urinary biomarkers for exposure to fumonisins. J. Nutr. 1999, 
129, 214-220.  Int. J. Mol. Sci. 2009, 10  
   
 
61
43.  Enongene, E.N.; Sharma, R.P.; Bhandari, N.; Voss, K.A.; Riley, R.T. Disruption of sphingolipid 
metabolism in small intestines, liver and kidney of mice dosed subcutaneously with fumonisin B1. 
Food Chem. Toxicol. 2000, 38, 793-799. 
44. Tran, S.T.; Bailly, J.D.; Tartdieu, D.; Durand, S.; Benard, G.; Guerre, P. Shinganine to 
sphingosine ratio and predictive biochemical markers of fumonisin B1 exposure in ducks. Chem. 
Biol. Interact. 2003, 46, 61-72. 
45. Gumprecht, L.A.; Marcucci, A.; Weigel, R.M.; Vesonder, R.F.; Riley, R.T.; Showker, J.L.; 
Beasley, V.R.; Haschek, W.M. Effects of intravenous Fumonisin B1 in rabbits: Nephrotoxicity 
and sphingolipid alterations. Nat. Toxins. 1995, 3, 395-403.  
46.  Laborde, J.B.; Terry, K.K.; Howard, P.C.; Chen, J.J.; Collins, T.F.; Shackelford, M.E.; Hansen, 
D.K. Effects of intravenous Fumonisin B1 in rabbits: Nephrotoxicity and sphingolipid alterations. 
Fundam. Appl. Toxicol. 1997, 40, 120-128.  
47.  Van der Westhuizen, L.; Shephard, G.S.; Van Schalkwyk, D.J. The effect of a single gavage dose 
of fumonisin B2 on the sphinganine and sphingosine concentrations in vervet monkeys. Food 
Chem. Toxicol. 2001, 39, 455-459.  
48. Soriano, J.M.; González, L.; Catalá, A.I. Mechanism of action of sphingolipids and their 
metabolites in the toxicity of fumonisin B1. Progr. Lipids Res. 2005, 44, 345-356. 
49.  Cai, Q.; Tang, L.; Wang, J.S. Validation of fumonisin biomarkers in F344 rats. Toxicol. Appl. 
Pharmacol. 2007, 225, 28-39. 
50.  Voss, K.A.; Riley, R.T.; Norred, W.P.; Bacon, C.W.; Meredith, F.I.; Howard, P.C.; Plattner, R.D.; 
Collins. T.F.X.; Hansen, D.K.; Porter, J.K. An overview of rodent toxicities: Liver and kidney 
effects of fumonisins and Fusarium moniliforme. Environ. Health Perspect. 2001, 109, 259-266. 
51. Delongchamp, R.R.; Young, J.F. Tissue sphinganine as a biomarker of fumonisin-induced 
apoptosis. Food Addit. Contam. 2001, 18, 255-261. 
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This article is an open-access article distributed under the terms and conditions of the Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 
 